IRIDEX Corporation (IRIX) AI Stock Analysis

IRIDEX Corporation is a provider of advanced ophthalmic medical technologies, specializing in therapeutic laser systems, delivery devices, and consumable instrumentation designed to combat sight-threatening eye diseases. Its product portfolio features laser consoles such as the Cyclo G6 system for treating glaucoma, and the IQ 532 and IQ 577 systems for laser photocoagulation in retinal conditions. It also offers the OcuLight series, the TxCell scanning laser delivery system, slit lamp adapters, laser indirect ophthalmoscopes, and specialized probes like the MicroPulse P3 Probe and G-Probe series. Founded in 1989 and based in Mountain View, California, IRIDEX serves ophthalmologists, hospitals, and surgical centers worldwide.

From FY2021 to FY2025, revenue grew at a 5-year CAGR of 7.7%, shifting from $53.9M in FY2021 to $57.0M in FY2022, then declining to $51.9M in FY2023 and $48.7M in FY2024, before rebounding 8.2% to $52.7M in FY2025. Gross margin contracted over this period from 42.4% in FY2021 to 36.7% in FY2025. Net income remained negative throughout, improving from -$5.2M in FY2021 and -$9.6M in FY2023 to -$4.4M in FY2025, alongside an operating margin improvement to -4.9%. In the latest quarter ended June 30, 2026, revenue dropped 7.4% year-over-year, while trailing twelve-month revenue totaled $51.6M with an EPS of -$0.20.

As of June 30, 2026, IRIDEX held $4.7M in cash and short-term investments against total debt of $4.0M, resulting in net cash of $667,000. Total assets stood at $27.3M and shareholders' equity was $3.6M, yielding a debt-to-equity ratio of 1.10 and a current ratio of 1.82. In FY2025, free cash flow was -$2.3M on operating cash flow of -$2.1M and capital expenditures of $143,000. Over five years, the share count increased by 9.5%.

At a market cap of $14.3M and an enterprise value of $16.5M, IRIDEX trades at a price-to-sales ratio of 0.3x and an EV-to-revenue ratio of 0.3x, well below the median of its US-listed Healthcare peers of 4.1x price-to-sales. Its forward P/E stands at 769.2x compared to the peer median of 17.3x, with a price-to-book ratio of 331.2x. Over the past year, IRIX shares fell 22.4%, while the S&P 500 returned 16.8%. Over five years, the stock dropped 89.0% compared to an 83.0% gain for the index.

Wall Street coverage includes 1 analyst rating, categorized as Strong Buy, with 0 Buy, Hold, Sell, or Strong Sell ratings. The mean price target is $2.75, representing an upside of 237.6% above the last close of $0.81. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $52.5M and an EPS of -$0.12. For the next fiscal year, projected revenue is $56.0M with break-even EPS of $0.00. IRIDEX beat EPS estimates in 2 of the last 4 quarters, with the next earnings release scheduled for November 10, 2026.

This page is an AI-written research summary of IRIDEX Corporation (IRIX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: IRIX income statement, IRIX balance sheet, IRIX key metrics, IRIX analyst forecast, IRIX chart. See the IRIX stock overview for the latest quote and news.